Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

We focus on these outcomes here because significant results were observed in unexpected tissues for IBD, Vitamin D and AD, while CAD showed the largest number of associated tissues.Heatmap highlighting relative deviations in gene expression of disease genes (vs control genes) for three major conditions across cell types obtained from the Tabula Sapiens dataset. a, Tabula Sapiens datasets were downloaded for each tissue, and absolute and relative expression levels were calculated for each cell type in each tissue. b, Results for inflammatory bowel disease. c, Results for coronary artery disease. d.

Source: The gene expression landscape at the cell-type level. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Laboratory / cell research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

EBV-transformed lymphocytes and Leukemia cell lines); (3) we scaled the expression of each tissue such that the total is 106 TPM.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The gene expression landscape of disease genes

Study design awaiting verification · Genome Biology · 2026

Original publication title

The gene expression landscape of disease genes

Judit García-González; Alanna C. Cote; Saul Garcia-Gonzalez; Lathan Liou; Paul F. O’Reilly

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We provide our systematic testing framework as an open-source, publicly available tool that can be utilised to offer novel insights into the genes, tissues and cell types involved in any disease, with the potential for informing drug development and delivery strategies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Fine-mapping and gene-prioritisation techniques applied to the latest genome-wide association study (GWAS) results have prioritised hundreds of genes as causally associated with disease. Here we leverage these recently compiled lists of high-confidence causal genes to interrogate where in the body disease genes operate, providing a more direct approach than previous studies, which have primarily relied on the enrichment of GWAS signals among genes with cell: or tissue-specific expression.

Source: Background

Abstract: Results

By integrating GWAS summary statistics, gene prioritisation results, and RNA-seq data from 46 tissues and 204 cell types, we directly analyse the gene expression of putative disease genes across the body in relation to 11 major diseases and cancers. In tissues and cell types with established disease relevance, disease genes show higher and more specific gene expression compared to control genes. Moreover, we detect elevated expression in tissues and cell types without previous links to the corresponding disease. While some of these results may be explained by cell types that span multiple tissues, such as macrophages in brain, blood, lung and spleen in relation to Alzheimer’s disease (P-values < 10: 3), the cause for others is unclear and warrants further investigation.

To support functional follow-up studies of disease genes, we identify technical and biological factors influencing their expression. Finally, we highlight tissue-disease pairs in which significantly elevated expression is associated with increased odds of inclusion in drug development programmes.

Source: Results

Abstract: Conclusions

We provide our systematic testing framework as an open-source, publicly available tool that can be utilised to offer novel insights into the genes, tissues and cell types involved in any disease, with the potential for informing drug development and delivery strategies.

Source: Conclusions
Authors’ abstract

Background

Fine-mapping and gene-prioritisation techniques applied to the latest genome-wide association study (GWAS) results have prioritised hundreds of genes as causally associated with disease. Here we leverage these recently compiled lists of high-confidence causal genes to interrogate where in the body disease genes operate, providing a more direct approach than previous studies, which have primarily relied on the enrichment of GWAS signals among genes with cell: or tissue-specific expression.

Results

By integrating GWAS summary statistics, gene prioritisation results, and RNA-seq data from 46 tissues and 204 cell types, we directly analyse the gene expression of putative disease genes across the body in relation to 11 major diseases and cancers. In tissues and cell types with established disease relevance, disease genes show higher and more specific gene expression compared to control genes. Moreover, we detect elevated expression in tissues and cell types without previous links to the corresponding disease. While some of these results may be explained by cell types that span multiple tissues, such as macrophages in brain, blood, lung and spleen in relation to Alzheimer’s disease (P-values < 10: 3), the cause for others is unclear and warrants further investigation.

To support functional follow-up studies of disease genes, we identify technical and biological factors influencing their expression. Finally, we highlight tissue-disease pairs in which significantly elevated expression is associated with increased odds of inclusion in drug development programmes.

Conclusions

We provide our systematic testing framework as an open-source, publicly available tool that can be utilised to offer novel insights into the genes, tissues and cell types involved in any disease, with the potential for informing drug development and delivery strategies.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13059-026-03958-7.

Publication and source details

Original title: The gene expression landscape of disease genes

Judit García-González; Alanna C. Cote; Saul Garcia-Gonzalez; Lathan Liou; Paul F. O’Reilly

Genome Biology · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Brain & Behavior Research Foundation30749http://dx.doi.org/10.13039/100000051National Human Genome Research Institute1K99HG013547-01National Institutes of HealthR01MH122866

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:06:24.972484+00:00

DOI: 10.1186/s13059-026-03958-7 · PMC12983648